Industry

Pipeline advances in 2026 span a range of dermatology disease areas, including atopic dermatitis, hidradenitis suppurativa, and alopecia areata, with 3 ongoing PoC/Phase II clinical studies* and 3 additional studies to be initiated in 2026. Almirall’s sustained trajectory of growth and profitability enables the company to reach more patients and supports a growth outlook of … [Read more…]

Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its rapid onset and efficacy through 6 months in both moderate-to-severe frown lines (glabellar lines) and crow’s feet (lateral canthal lines)1-3 Dysport® (AbobotulinumtoxinA) data demonstrating high levels of patient and practitioner satisfaction … [Read more…]

US$5.9M awarded to 11 organisations and high schools from the UAE, Brazil, Canada, Nepal, Switzerland, Uganda and across six sustainability categories From AI-enabled diagnostics to Cooling-as-a-Service, this year’s winners deliver locally adapted innovations that empower millions In 18 years, the Prize has scaled solutions reaching more than 411 million people globally ABU DHABI, United Arab … [Read more…]

Sponsorship reflects commitment to increasing access to care for orthodontic treatment especially for children, and Align’s support of the Canadian orthodontic profession TEMPE, Ariz.–(BUSINESS WIRE)–Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital … [Read more…]

ZHUZHOU, China & BOSTON–(BUSINESS WIRE)–Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for … [Read more…]

Two peptide programs validate the AnimateIQ™ platform with strong anti-fibrotic efficacy, improved systemic health and broad biological relevance SAN FRANCISCO–(BUSINESS WIRE)–Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that two of its AI-designed therapeutic peptides significantly reduced lung fibrosis and inflammation. Notably, the company’s lead peptide performed comparably … [Read more…]

Dr. Taz MD, The Pioneer of Doctor-led Evidence Based Holistic Medicine, transforms her 20+ years of experience into a comprehensive holistic health hub for the whole family ATLANTA–(BUSINESS WIRE)–#functionalmedicine—Dr. Taz Bhatia, a leading expert in modernized holistic medicine, integrating traditional healing with contemporary medical advancements, has reimagined the future of health with the launch of … [Read more…]

First phase 3 trial to prospectively enroll patients with tumors that test positively for TROP2 NMR, a novel computational pathology biomarker to identify those most likely to benefit from Daiichi Sankyo and AstraZeneca’s DATROWAY TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) … [Read more…]

BARCELONA & DEERFIELD, Ill.–(BUSINESS WIRE)–ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire TerSera’s Infusion Specialty Therapies Business Unit (IST). This strategic acquisition enables ESTEVE to expand its U.S. presence, with two highly specialized on-market assets and a dedicated team of sales, marketing and medical … [Read more…]

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant … [Read more…]